Jason Westin, MD

Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.

Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.

With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.

A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.

Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.

Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.

Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.

Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.

Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.

A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.

Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.

A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.

Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.

Jason R. Westin, MD, director, discusses how the approval of CAR T-cell therapies in the second-line setting has radically shifted preferred treatment approaches in relapsed/refractory large B-cell lymphoma.

Jason R. Westin, MD, discusses subgroup analysis of elderly patients treated in the ZUMA-7 trial.

Jason R. Westin, MD, discusses the evolving landscape of CAR T-cell therapy in non-Hodgkin lymphoma.

Jason R. Westin, MD, director, discusses the utilization of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.

Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.

Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.

Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.

Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.

Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.

Dr Miklos provides an overview of chimeric antigen receptor T (CAR-T) cell therapy.

Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.

Jason R. Westin, MD,discusses the patient-reported outcome data from the phase 3 TRANSFORM study in relapsed/ refractory large B-cell lymphoma.

Jason R. Westin, MD, discusses the 2-year follow-up data of the ongoing phase 1 TRANSCEND-NHL-001 trial in relapsed/refractory large B-cell lymphoma.

A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.